Redemption of shares in ChronTech Pharma AB

In accordance with the decision of the Extra General Meeting on the 6th of May, 2013, the Swedish Companies Registration Office has now registered the redemption of 80,274,295 shares in ChronTech Pharma AB. At the EGM on the 6th of May it was decided “a reduction of the share capital with 2,408,228,85 SEK to cover the loss through the redemption of 80,274,295 shares. Those shareholders who will acquire the part of the Company’s activities regarding development of DNA vaccines against hepatitis B and hepatitis C shall put 80,274,295 shares to the Company’s disposition for redemption”.

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@chrontech.se

About ChronTech

ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.